Literature DB >> 22132896

Preconditioning donor with a combination of tacrolimus and rapamacyn to decrease ischaemia-reperfusion injury in a rat syngenic kidney transplantation model.

F Cicora1, J Roberti, D Vasquez, D Guerrieri, N Lausada, P Cicora, G Palti, E Chuluyan, P Gonzalez, P Stringa, C Raimondi.   

Abstract

Reperfusion injury remains one of the major problems in transplantation. Repair from ischaemic acute renal failure (ARF) involves stimulation of tubular epithelial cell proliferation. The aim of this exploratory study was to evaluate the effects of preconditioning donor animals with rapamycin and tacrolimus to prevent ischaemia-reperfusion (I/R) injury. Twelve hours before nephrectomy, the donor animals received immunosuppressive drugs. The animals were divided into four groups, as follows: group 1 control: no treatment; group 2: rapamycin (2 mg/kg); group 3 FK506 (0, 3 mg/kg); and group 4: FK506 (0, 3 mg/kg) plus rapamycin (2 mg/kg). The left kidney was removed and after 3 h of cold ischaemia, the graft was transplanted. Twenty-four hours after transplant, the kidney was recovered for histological analysis and cytokine expression. Preconditioning treatment with rapamycin or tacrolimus significantly reduced blood urea nitrogen and creatinine compared with control [blood urea nitrogen (BUN): P < 0·001 versus control and creatinine: P < 0·001 versus control]. A further decrease was observed when rapamycin was combined with tacrolimus. Acute tubular necrosis was decreased significantly in donors treated with immunosuppressants compared with the control group (P < 0·001 versus control). Moreover, the number of apoptotic nuclei in the control group was higher compared with the treated groups (P < 0·001 versus control). Surprisingly, only rapamycin preconditioning treatment increased anti-apoptotic Bcl2 levels (P < 0·001). Finally, inflammatory cytokines, such as tumour necrosis factor (TNF)-α and interleukin (IL)-6, showed lower levels in the graft of those animals that had been pretreated with rapamycin or tacrolimus. This exploratory study demonstrates that preconditioning donor animals with rapamycin or tacrolimus improves clinical outcomes and reduce necrosis and apoptosis in kidney I/R injury.
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22132896      PMCID: PMC3248098          DOI: 10.1111/j.1365-2249.2011.04487.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  54 in total

1.  Protective effect of immunosuppressive treatment before orthotopic kidney autotransplantation.

Authors:  Federico Cicora; Natalia Lausada; Daniela N Vasquez; Paola Cicora; Diego Guerrieri; Pedro Gonzalez; Gustavo Zalazar; Pablo Stringa; Clemente Raimondi
Journal:  Transpl Immunol       Date:  2010-10-27       Impact factor: 1.708

Review 2.  The interaction between ischemia-reperfusion and immune responses in the kidney.

Authors:  Hye Ryoun Jang; Gang Jee Ko; Barbara A Wasowska; Hamid Rabb
Journal:  J Mol Med (Berl)       Date:  2009-06-28       Impact factor: 4.599

Review 3.  Triggers of inflammation after renal ischemia/reperfusion.

Authors:  Joshua M Thurman
Journal:  Clin Immunol       Date:  2006-10-24       Impact factor: 3.969

4.  Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells.

Authors:  Heather Kopf; Gonzalo M de la Rosa; O M Zack Howard; Xin Chen
Journal:  Int Immunopharmacol       Date:  2007-09-20       Impact factor: 4.932

5.  Rapamycin suppresses TLR4-triggered IL-6 and PGE(2) production of colon cancer cells by inhibiting TLR4 expression and NF-kappaB activation.

Authors:  Qiaoling Sun; Qiuyang Liu; Yuanyuan Zheng; Xuetao Cao
Journal:  Mol Immunol       Date:  2008-03-17       Impact factor: 4.407

6.  Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial.

Authors:  Katja Kotsch; Frank Ulrich; Anja Reutzel-Selke; Andreas Pascher; W Faber; P Warnick; S Hoffman; M Francuski; C Kunert; O Kuecuek; G Schumacher; C Wesslau; A Lun; S Kohler; S Weiss; S G Tullius; P Neuhaus; Johann Pratschke
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

7.  Atorvastatin donor pretreatment prevents ischemia/reperfusion injury in renal transplantation in rats: possible role for aldose-reductase inhibition.

Authors:  Uwe Gottmann; Paul T Brinkkoetter; Simone Hoeger; Katrin Gutermann; Zora Martins Coutinho; Tobias Ruf; Song Hui; Zhenzi Liu; Peter Schnuelle; Fokko J van der Woude; Claude Braun; Benito A Yard
Journal:  Transplantation       Date:  2007-09-27       Impact factor: 4.939

8.  Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation.

Authors:  Xiaohai Guan; Genevieve Dei-Anane; Rui Liang; Marie-Luise Gross; Arash Nickkholgh; Michael Kern; Jochen Ludwig; Martin Zeier; Markus W Büchler; Jan Schmidt; Peter Schemmer
Journal:  J Surg Res       Date:  2007-07-25       Impact factor: 2.192

9.  Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation.

Authors:  Fuad S Shihab; William M Bennett; Takeshi F Andoh
Journal:  Transplantation       Date:  2009-02-15       Impact factor: 4.939

10.  The role of immunosuppressive drugs in aggravating renal ischemia and reperfusion injury.

Authors:  G M Gonçalves; M A Cenedeze; C Q Feitoza; C B de Paula; G D Marques; H S Pinheiro; V de Paula Antunes Teixeira; M Antônia dos Reis; A Pacheco-Silva; N O S Câmara
Journal:  Transplant Proc       Date:  2007-03       Impact factor: 1.066

View more
  5 in total

Review 1.  Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.

Authors:  Daniel Fantus; Natasha M Rogers; Florian Grahammer; Tobias B Huber; Angus W Thomson
Journal:  Nat Rev Nephrol       Date:  2016-08-01       Impact factor: 28.314

2.  Modulation of Immunologic Response by Preventive Everolimus Application in a Rat CPB Model.

Authors:  Antonio Pinto; Annika Jahn; Moritz Benjamin Immohr; Alexander Jenke; Laura Döhrn; Markus Kornfeld; Artur Lichtenberg; Payam Akhyari; Udo Boeken
Journal:  Inflammation       Date:  2016-10       Impact factor: 4.092

Review 3.  mTOR Signaling in Kidney Diseases.

Authors:  Yuan Gui; Chunsun Dai
Journal:  Kidney360       Date:  2020-09-03

Review 4.  Mechanisms of Caloric Restriction-Mediated Stress-Resistance in Acute Kidney Injury.

Authors:  Felix C Koehler; Martin R Späth; K Johanna R Hoyer-Allo; Roman-Ulrich Müller
Journal:  Nephron       Date:  2021-08-02       Impact factor: 3.457

5.  Oxidative stress and apoptosis in a pig model of brain death (BD) and living donation (LD).

Authors:  Philipp Stiegler; Michael Sereinigg; Andreas Puntschart; Andrea Bradatsch; Thomas Seifert-Held; Iris Wiederstein-Grasser; Bettina Leber; Elke Stadelmeyer; Nadia Dandachi; Siglinde Zelzer; Florian Iberer; Vanessa Stadlbauer
Journal:  J Transl Med       Date:  2013-10-02       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.